Traditional treatment strategies have largely been limited to pharmaceutical and surgical modalities. Currently approved medications, such as Finasteride and Minoxidil, require a great degree of compliance for long periods of time with varying degrees of effectiveness. Side effects are also common and often dissuade use, including sexual dysfunction, mood disorders, increased risks of prostate/breast cancer, and birth defects. Surgical treatments, once limited to scalp reduction and rotational flap techniques, have evolved to follicular unit isolation/extraction with the use of punch biopsies or donor strip harvesting. Success and efficiency are affected by surgeon skill set, however, because follicle transection rates and operative speed are limiting factors for both physician and patient. In addition, scar, poor wound healing, and an unnatural hairline are frequently reported concerns and considerations in the hands of less experienced surgeons. Recent discoveries in the molecular pathways of the hair cycle, however, have provided the foundation for novel investigations in a “biologically oriented” approach to cell based therapies in hair restoration.


The use of platelet concentrates in regenerative medicine has long been investigated in several surgical and clinical fields. The effects of these concentrates on bone grafting and wound healing have been demonstrated in oral and maxillofacial, orthopedic, and cardiac surgery. More recently, interest has been increasing in dermatology and plastic surgery in both fat grafting and skin rejuvenation. Essential to wound repair and the inflammatory/remodeling pathway, platelets contain several chemotactic and mitogenic proteins that are released upon activation; growth hormones and cytokines are among the most prominent biologically active and secreted components. Platelet-rich plasma (PRP) is an autogenous, liquid, platelet concentrate that is extracted from a patient’s peripheral blood by a centrifugation process. Because PRP is autologous, the risk of hypersensitivity or immunogenic reactions and disease transmission is significantly reduced. The platelet and plasma growth factors isolated in the PRP slurry have been found to be in higher concentration per volume, when compared with a patient’s whole blood. The platelet solution may then be activated in vitro (turning to a gelatinous state) or injected in liquid form for activation in vivo. Once activated, platelets release alpha granules containing a myriad of growth factors, including transforming growth factor-ß (TGF-ß), epidermal growth factor (EGF), basic fibroblast growth factor, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and insulin-like growth factor-1 (IGF-1). These factors have been found to have substantial effects on the hair cell growth cycle: stimulating differentiation proliferation, and hair follicle growth. In brief, the hair cycle consists of a resting telogen phase, an active anagen growing phase, and an apoptotic catagen phase. Aberrancies in the cycling of these phases lead to a disruption in hair follicle growth and hair loss. Bulge cells, inducible stem cells found along the shaft of the hair follicle, have been found to repopulate the hair follicle epithelium and are fundamental to the progression of hair cycling. It is these hair follicle stem cells that contain growth factor receptors responsible for hair growth manipulation and molecular pathway regulation.


Laboratory tests to aid with diagnosis include complete blood cell count; and measurement of serum levels of iron, serum ferritin, total iron-binding capacity, folic acid, triiodothyronine, thyroxine, thyroid-stimulating hormone, antithyroid peroxidase, dehydroepiandrosterone, testosterone, prolactin, follicle stimulating hormone, and luteinizing hormone. Of note, medication history known to affect the cyclooxygenase inflammatory pathway should be documented; these include nonsteroidal anti-inflammatory drugs such as aspirin, glucocorticoids, and immunomodulating therapies.


Contraindications and exclusion criteria in several studies include coagulation disorders, platelet dysfunction, anticoagulant therapy, thrombocytopenia, hemodynamic instability, local infection at the site of blood harvest or graft injection, hepatitis, and patients who are prone to keloid formation.


The production of platelet concentrates for platelet-rich solutions begins with the harvest of peripheral venous blood. Care is taken to reduce platelet injury/fragmentation because mechanical trauma may result in unintentional activation; these measures include the use of large-bore needles and single needle-stick venipuncture attempts. The collected specimen can be centrifuged in 1 or 2 steps depending on the preparation system. The initial, low-force, centrifugation allows the blood components to separate into 3 weight-dependent layers: (1) a top, supernatant, layer of platelet-poor plasma (PPP); (2) a “buffy coat” (BC) middle layer rich in platelets and containing white blood cells; (3) a bottom, red blood cell (RBC) layer. The second step varies among the numerous protocols, however, in concept and is an attempt to discard both the RBC and the PPP layers. This is mediated by harvesting the PPP and BC layers following the first centrifugation into a separate test tube. Under high centrifugal force, the platelet-rich layer and plasma supernatant are further separated, improving the precipitant yield of platelets from plasma. The final liquid platelet suspension coined PRP aims to be enriched 4 to 7 times that of whole blood to be considered therapeutically effective, shown to be approximately 1 to 1.5 million platelets per microliter to induce mesenchymal stem cell proliferation. Values greater than 1.5 million platelets per microliter have been found to decrease angiogenesis.

The US regulatory process for blood products is described in the Food and Drug Administration’s (FDA) 21 CFR 127 of the Code of Regulations73; this is under the prevue of the FDA’s Center for Biologics Evaluation and Research.

Kolors offers RICH PRP (30 ml) Tricel PRP FDA approved technique.



1- We follow PROCEDURE in OT with the complete sterile medium for procedures.

2- Our expert surgeon have over 3 years of experience and are trained in-house for dealing with all sorts of related conditions

3- Centrifuge machine used to activate the platelets is US-FDA approved Tricel PRP (30ml).

4- No infection, allergies or side effects are seen in this treatment at Kolors.

Holistic approach for the treatment of hair with diet, supplemental and in house kits provided.